Simple but highly effective three-dimensional chemical-feature-based pharmacophore model for diketo acid derivatives as hepatitis C virus RNA-dependent RNA polymerase inhibitors

被引:44
作者
Di Santo, R
Fermeglia, M
Ferrone, M
Paneni, MS
Costi, R
Artico, M
Roux, A
Gabriele, M
Tardif, KD
Siddiqui, A
Pricl, S
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy
[2] Univ Trieste, Dept Chem Engn, MOSE, I-34127 Trieste, Italy
[3] Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA
[4] Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA
[5] Univ Calif San Diego, Dept Med, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA
关键词
D O I
10.1021/jm0504454
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A molecular modeling strategy using aryl diketo acid (ADK) derivatives recently reported in the literature as hepatitis C virus (HCV) polymerase inhibitors was designed. A 3D chemical-feature-based pharmacophore model was developed using Catalyst software, which produced 10 pharmacophore hypotheses. The top-ranked one (Hypo 1), characterized by a high correlation coefficient (r = 0.965), consisted of two hydrogen bond acceptors, one negative ionizable moiety, and two hydrophobic aromatics. This model was used to predict the anti-RNA-dependent RNA polymerase (anti-RdRp) activity of 6-(1-arylmethylpyrrol-2-yl)-1,4-dioxo-5-hexenoic acids and other ADK derivatives previously synthesized in our laboratories as HIV-1 integrase inhibitors. Furthermore, the experimental IC50 values of 9 compounds, tested in vitro against recombinant HCV polymerase, were compared with the corresponding values predicted using Hypo1. A good agreement between experimental and simulated data was obtained. The results demonstrate that the hypothesis derived in this study can be considered to be a useful tool in designing new leads based on ADK scaffolds as HCV RdRp inhibitors.
引用
收藏
页码:6304 / 6314
页数:11
相关论文
共 48 条
[1]  
*ACC INC, 2003, CAT VERS 4 9
[2]   Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus [J].
Ago, H ;
Adachi, T ;
Yoshida, A ;
Yamamoto, M ;
Habuka, N ;
Yatsunami, K ;
Miyano, M .
STRUCTURE, 1999, 7 (11) :1417-1426
[3]  
ALTAMURA S, 2000, Patent No. 200006529
[4]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[5]  
[Anonymous], FIELDS VIROLOGY
[6]   INHIBITION OF COPPER-DEPENDENT AMINE OXIDASES BY SOME HYDRAZIDES OF PYRROL-1-YLBENZOIC AND PYRROL-1-YLPHENYLACETIC ACIDS [J].
ARTICO, M ;
CORELLI, F ;
MASSA, S ;
STEFANCICH, G ;
AVIGLIANO, L ;
BEFANI, O ;
MARCOZZI, G ;
SABATINI, S ;
MONDOVI, B .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (04) :802-806
[7]   Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus [J].
Behrens, SE ;
Tomei, L ;
DeFrancesco, R .
EMBO JOURNAL, 1996, 15 (01) :12-22
[8]   Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus [J].
Bressanelli, S ;
Tomei, L ;
Roussel, A ;
Incitti, I ;
Vitale, RL ;
Mathieu, M ;
De Francesco, R ;
Rey, FA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) :13034-13039
[9]   Applicability of CATALYST in ecotoxicology, a new promising tool for 3D-QSAR: Study of chlorophenols [J].
Briens, F ;
Bureau, R ;
Rault, S .
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 1999, 43 (03) :241-251
[10]   CHARMM - A PROGRAM FOR MACROMOLECULAR ENERGY, MINIMIZATION, AND DYNAMICS CALCULATIONS [J].
BROOKS, BR ;
BRUCCOLERI, RE ;
OLAFSON, BD ;
STATES, DJ ;
SWAMINATHAN, S ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1983, 4 (02) :187-217